PTPRK and neoplasm: Our findings add a new twist to this mystery as we reveal that RAS at the GC, which includes H- and N- isoforms but not KRAS, actually antagonize tumor formation through induction of PTPRκ that downregulates ERK activity, the engine at the heart of RAS transformation.